PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice

BACKGROUND: Several lipid guidelines recommend that proprotein convertase subtilisin/kexin type 9 inhibitors should be considered for patients with atherosclerotic cardiovascular disease who are inadequately treated with maximally tolerated lipid-lowering treatment. OBJECTIVES: The PEARL study asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Parhofer, Klaus G., von Stritzky, Berndt, Pietschmann, Nicole, Dorn, Cornelia, Paar, W. Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702526/
https://www.ncbi.nlm.nih.gov/pubmed/31280466
http://dx.doi.org/10.1007/s40801-019-0158-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702526/
https://www.ncbi.nlm.nih.gov/pubmed/31280466
http://dx.doi.org/10.1007/s40801-019-0158-0

Ejemplares similares